TABLE 2.
Efficacies of tedizolid, vancomycin, and linezolid in a murine subcutaneous catheter-related infection due to MRSA strain Xen30
| Regimen (no. of samples) | Mean log10 no. of CFU/catheter ± SD | P value(s) |
|---|---|---|
| Treatmenta | ||
| Control (20) | 7.14 ± 0.37 | |
| Tedizolid phosphate, 10 mg/kg i.v. bid (20) | 5.70 ± 0.53 | <3.07E−06 vs control, <0.03 vs linezolid, <0.002 vs vancomycin |
| Linezolid, 80 mg/kg i.v. bid (20) | 6.47 ± 0.57 | <0.05 vs control |
| Vancomycin, 110 mg/kg s.c. bid (20) | 6.64 ± 0.83 | <0.07 vs control |
| Relapse | ||
| Control (20) | 6.63 ± 0.53 | |
| Tedizolid phosphate, 10 mg/kg i.v. bid (20) | 5.34 ± 0.73 | <0.0002 vs control relapse |
a
Treatment lasted 6 days.